WG
NKTR icon

Winton Group’s Nektar Therapeutics NKTR Stock Holding History

Winton Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Buy
16,910
+9,145
+118% +$521K 0.04% 477
2025
Q4 		$328K Buy
+7,765
New +$435K 0.01% 726
2020
Q4 		– Sell
-3,046
Closed -$758K – 1452
2020
Q3 		$758K Sell
3,046
-3,770
-55% -$1.19M 0.02% 937
2020
Q2 		$2.37M Sell
6,816
-701
-9% -$219K 0.06% 569
2020
Q1 		$2.01M Sell
7,517
-9,367
-55% -$2.9M 0.05% 574
2019
Q4 		$5.47M Buy
16,884
+13,561
+408% +$3.93M 0.08% 433
2019
Q3 		$908K Buy
3,323
+2,837
+584% +$1.04M 0.01% 878
2019
Q2 		$259K Buy
486
+36
+8% +$18.1K 0.01% 945
2019
Q1 		$227K Sell
450
-230
-34% -$136K ﹤0.01% 912
2018
Q4 		$335K Buy
680
+196
+40% +$118K 0.01% 622
2018
Q3 		$443K Sell
484
-28
-5% -$23.9K 0.01% 677
2018
Q2 		$375K Buy
512
+149
+41% +$172K 0.01% 738
2018
Q1 		$579K Buy
+363
New +$468K 0.02% 704

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Winton Group's NKTR Position: Q1 2026 in Review

Winton Group increased its Nektar Therapeutics (NKTR) stake by 118% in Q1 2026, buying an estimated $521K and bringing the position to 16,910 shares worth $1.22M. The position accounts for 0.04% of the portfolio, ranked #477.

Winton Group first reported a position in NKTR in Q1 2018 and has held it in 13 quarters since. The position peaked at $5.47M in Q4 2019. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Winton Group held 16,910 shares of Nektar Therapeutics worth $1.22M as of Q1 2026.
  • Winton Group bought 9,145 Nektar Therapeutics shares in Q1 2026, an estimated $521K.
  • Nektar Therapeutics made up 0.04% of Winton Group's portfolio in Q1 2026, its #477 holding.
  • Winton Group first reported a position in Nektar Therapeutics in Q1 2018 and has held it in 13 quarters since.
  • Winton Group's Nektar Therapeutics position peaked at $5.47M in Q4 2019.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.